Previous studies also demonstrated that PRMT3 was involved in tumor progression and therapy resistance in several cancer types, including colorectal cancer, pancreatic cancer, endometrial carcinoma, and glioblastoma44,45,63,64. Here, PRMT3 is linked to endometrial carcinoma.